Contact Us
Contact Us
Contact Us

Investors

Welcome to our Investor page. Here you will find information on the latest ASX announcements, investor presentations and other shareholder information on Race Oncology.

Race Oncology

Race Oncology is a specialty pharmaceutical company focused on rediscovering and rescuing life-saving drugs that can deliver early commercial milestones. Race Oncology’s first asset is Bisantrene, a small molecule Chemotherapy drug that has been evaluated clinically for Acute Myeloid Leukaemia (AML).

ASX Announcements



DateTitle
21/05/2020Final Director's Interest NoticeDownload
20/05/2020Managing Director ResignationDownload
18/05/2020Trading HaltDownload
18/05/2020Pause in TradingDownload
14/05/2020Race starts preclinical breast cancer study for BisantreneDownload
22/04/2020Quarterly Activity Report & Appendix 4CDownload
23/03/2020Notification of Lapse of Unlisted OptionsDownload
20/03/2020Notification of Expiry of Unlisted OptionsDownload
18/03/2020Phase II Bisantrene Trial Recruitment CompletedDownload
13/03/2020Appendix 2ADownload
1  2  3  4  

ASX: RAC

Price

Latest News

Read All Stories

Don't miss important updates

Get the latest news & announcement and stay up-to-date.

© 2020 Race Oncology. Website By Multiplier